These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18804799)

  • 1. Re: Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer: M. J. Zelefsky, V. E. Reuter, Z. Fuks, P. Scardino and A. Shippy. J Urol 2008; 179: 1368-1373.
    Coquard R
    J Urol; 2008 Nov; 180(5):2258; author reply 2258. PubMed ID: 18804799
    [No Abstract]   [Full Text] [Related]  

  • 2. Is radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy?
    Van Poppel H
    Eur Urol; 2009 May; 55(5):1012-3. PubMed ID: 19261377
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial I. M. Thompson, C. M. Tangen, J. Paradelo, M. S. Lucia, G. Miller, D. Troyer, E. Messing, J. Forman, J. Chin, G. Swanson, E. Canby-Hagino and E. D. Crawford J Urol 2009; 181: 956-962.
    Cheng T; Heng DY; Stewart D
    J Urol; 2009 Nov; 182(5):2531-2; discussion 2532-4. PubMed ID: 19766252
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical assessment of outcome of prostate cancer (TCP, NTCP).
    Perez CA; Michalski J; Mansur D
    Rays; 2005; 30(2):109-20. PubMed ID: 16294903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
    Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials.
    Roach M
    J Clin Oncol; 2008 Aug; 26(22):3816-7; author reply 3817-8. PubMed ID: 18669477
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of conformal and intensity modulated treatment planning techniques for early prostate cancer.
    Vaarkamp J; Malde R; Dixit S; Hamilton CS
    J Med Imaging Radiat Oncol; 2009 Jun; 53(3):310-7. PubMed ID: 19624299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional conformal radiation therapy for early prostate cancer.
    Peschel RE
    Cancer J Sci Am; 1999; 5(3):145-6. PubMed ID: 10367168
    [No Abstract]   [Full Text] [Related]  

  • 12. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
    Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy.
    Chen SW; Yang SN; Liang JA; Lin FJ; Tsai MH
    Head Neck; 2009 Jun; 31(6):709-16. PubMed ID: 19260114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved quality of life following radical radiation therapy for early stage carcinoma of the prostate.
    Leibel SA; Pino y Torres JL; Order SE
    Urol Clin North Am; 1980 Oct; 7(3):593-604. PubMed ID: 7456172
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1% K. Touijer, F. Rabbani, J. R. Otero, F. P. Secin, J. A. Eastham, P. T. Scardino And B. Guillonneau J Urol 2007; 178: 120-124.
    Joseph JV; Greene T
    J Urol; 2008 Feb; 179(2):789-90. PubMed ID: 18082824
    [No Abstract]   [Full Text] [Related]  

  • 16. Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer.
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Lief JH; Adamovich E
    Am J Clin Oncol; 2008 Dec; 31(6):539-44. PubMed ID: 19060584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [External beam radiotherapy for prostate cancer].
    Nakamura K; Sasaki T; Shioyama Y; Oga S; Terashima H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():235-9. PubMed ID: 12599577
    [No Abstract]   [Full Text] [Related]  

  • 18. Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan.
    Sasaki T; Nakamura K; Ogawa K; Onishi H; Okamoto A; Koizumi M; Shioyama Y; Mitsumori M; Teshima T;
    BJU Int; 2009 Nov; 104(10):1462-6. PubMed ID: 19522869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How quality influences the clinical outcome of external beam radiotherapy for localized prostate cancer.
    van Vulpen M; van der Heide UA; van Moorselaar JR
    BJU Int; 2008 Apr; 101(8):944-7. PubMed ID: 18070170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.